When stratifying by autoantibody profile, SSA/SSB double‐positive patients displayed a significantly increased risk for cerebral infarction (HR 1.7, 95% CI 1.0–2.9), which was not observed in patients single positive or negative for these autoantibodies (Table 2). This evidence concerns the gene TRIM21 and brain infarction.